Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Metabolic Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APLNR drug discovery, covering multiple modalities.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | APLNR ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View APLNR Products |
| Gene Delivery | APLNR Full-Length Lentivirus Premade Particles. High-titer, ready for stable cell line construction. Preserves native GPCR conformation for functional assays. | View APLNR Products |
| Benchmark Ab & Ligand | Anti-APLNR Antibody & Recombinant Apelin-13/Apelin-17/ELABELA. Research-grade positive controls for binding and activation assays. Sequence Verified. | View APLNR Products |
| Validator | APLNR siRNA Set. For knockdown verification and specificity controls in cell-based signaling assays. | View APLNR Products |
| Related Target A | APLN (Apelin). Endogenous ligand required for co-receptor and pathway reconstitution assays. | View APLN Products |
| Related Target B | ELABELA (Toddler). Alternative endogenous ligand; distinct binding epitope for biased agonist studies. | View ELABELA Products |
| Related Target C | AGTR1 (Angiotensin II Receptor Type 1). Cardiovascular counter-screening target; assess selectivity within RAAS-associated GPCR networks. | View AGTR1 Products |
| Related Target D | CXCR4. Chemokine receptor physically associating with APLNR in endothelial cell signaling and angiogenesis. | View CXCR4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR conformation and signaling | Lentivirus-mediated full-length APLNR expression in HEK293. Optimized for Calcium Flux, cAMP HTRF, and GloSensor assays. |
| Cross-species cardiovascular translation | Human / Mouse / Rat / Cynomolgus APLNR ortholog lentivirus and proteins available with >95% purity and NGS-verified sequences. |
| Biased signaling detection (G protein vs β-arrestin) | Stable cell lines with functional readouts for Gq/Gi (cAMP, Ca2+) and β-arrestin recruitment; critical for biased agonist screening. |
| Assay specificity and endogenous background | APLNR siRNA included for knockdown verification; removal of false positive signals in native cell lines. |
| Ligand binding kinetics (SPR/BLI) | High-purity APLNR ECD-Fc with theoretical MW confirmed; endotoxin controlled for sensitive cell and biophysical assays. |
| Receptor internalization & trafficking | High-titer lentivirus enables stable expression for flow cytometry-based surface receptor dynamics studies. |
Live APLNR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for APLNR (APJ) therapeutics is intensifying, with major players shifting focus from short-lived endogenous peptides to synthetic biased agonists and half-life extended modulators. First-generation apelin analogs have demonstrated hemodynamic benefit in heart failure and pulmonary arterial hypertension (PAH), with compounds such as MEDI6012 (AstraZeneca/MedImmune) advancing through Phase II. However, rapid receptor desensitization via β-arrestin recruitment remains a key limitation. Consequently, the next wave of R&D is heavily targeting G-protein-biased small molecules and biased ligands that minimize β-arrestin-mediated internalization, aiming to sustain vasodilation and inotropic effects. Beyond cardiovascular indications, APLNR is being explored in metabolic syndrome, diabetic nephropathy, and as a resistance bypass pathway in VEGF-inhibitor-treated tumors, expanding the therapeutic horizon.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonists (Half-life Extended) | AstraZeneca/MedImmune, Amgen, Elpis Biopharmaceuticals | Heart Failure (HFrEF/HFpEF), Pulmonary Arterial Hypertension | Cell-based functional assays using lentivirus-stable APLNR lines; receptor internalization assessment |
| Small Molecule Biased Agonists | Bristol Myers Squibb, Novo Nordisk, CohBar | Cardiometabolic Diseases, Chronic HF | cAMP vs. β-arrestin pathway selectivity screening; multi-species ortholog panels |
| Biased Ligands (G-protein biased) | Translational academic consortia, Amgen | Cardioprotection, Ischemia-Reperfusion Injury | β-arrestin vs. G-protein pathway dissection; Ca2+ flux assays |
| Monoclonal Antibodies | Various biotechs | Vascular/Angiogenesis, Oncology | Flow cytometry binding using high-purity positive control antibodies |
| Combination Therapy | RAAS-focused developers | Resistant hypertension, Fibrosis | APLNR + AGTR1 dual-target cell models; selectivity counterscreening |